Vigil
Advanced Recurrent Ovarian Cancer (cTMB-H/HRP subgroup)
Phase 2bActive
Key Facts
Indication
Advanced Recurrent Ovarian Cancer (cTMB-H/HRP subgroup)
Phase
Phase 2b
Status
Active
Company
About Gradalis
Gradalis is a private, late-stage biotech advancing Vigil, a personalized cancer immunotherapy platform. Its lead program has demonstrated a significant survival benefit in a subset of ovarian cancer patients in a Phase 2b trial, with data published in a peer-reviewed journal. The company is positioning Vigil as a potential treatment for various solid tumors, either as a monotherapy or in combination with other regimens, representing a targeted approach in the immuno-oncology space.
View full company profile